Davenport & Co’s INmune Bio INMB Stock Holding History

Davenport & Co’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$19.5K	Hold	10,000	–	–	﹤0.01%	1387
2026 Q2	$16.3K	Hold	10,000	–	–	﹤0.01%	1352
2026 Q1	$11.3K	Hold	10,000	–	–	﹤0.01%	1300
2025 Q4	$15.6K	Hold	10,000	–	–	﹤0.01%	1251
2025 Q3	$20.7K	Hold	10,000	–	–	﹤0.01%	1223
2025 Q2	$23.1K	Buy	+10,000	New	+$73.4K	﹤0.01%	1199

Other funds holding INMB

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Bill Few Associates Pittsburgh, Pennsylvania $485M AUM 17.8% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Davenport & Co's INMB Position: Q3 2026 in Review

Davenport & Co held its INmune Bio (INMB) position steady in Q3 2026 at 10,000 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1387.

Davenport & Co first reported a position in INMB in Q2 2025 and has held it in 6 quarters since. The position peaked at $23.1K in Q2 2025. 7 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

Davenport & Co held 10,000 shares of INmune Bio worth $19.5K as of Q3 2026.
Davenport & Co left its INmune Bio share count unchanged in Q3 2026.
INmune Bio made up ﹤0.01% of Davenport & Co's portfolio in Q3 2026, its #1387 holding.
Davenport & Co first reported a position in INmune Bio in Q2 2025 and has held it in 6 quarters since.
Davenport & Co's INmune Bio position peaked at $23.1K in Q2 2025.
7 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.